NEW MJ NEWS

Trulieve to Open Medical Cannabis Dispensary in Orlando, Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company in the U.S., today announced the opening of a new medical cannabis dispensary in Orlando, Florida.

A grand opening celebration will be held Friday, October 25, beginning at 9 a.m., featuring music, specials, discounts, and opportunities to register for upcoming patient education sessions as well as learn about #YesOn3 and the ballot initiative to legalize adult cannabis use in Florida.

“This new dispensary offers greater convenience to patients and caregivers in the Orlando area,” said Trulieve’s Chief Executive Officer Kim Rivers. “We look forward to serving customers in western Orange County with affordable, high-quality products and outstanding customer service.”

Trulieve Orlando West Colonial, located at 7225 West Colonial Drive, Unit 100, will be open 9 a.m. – 8:30 p.m. Monday through Saturday and 11 a.m. – 8 p.m. on Sundays, offering walk-in and express pickup service.

The new dispensary will carry a wide variety of popular products including Trulieve’s portfolio of in-house brands such as Alchemy, Co2lors, Cultivar Collection, Modern Flower, Momenta, Muse, Roll One, Sweet Talk, and Trekkers. Customers will also have access to beloved partner brands such as Alien Labs, Bellamy Brothers, Binske, Black Tuna, Blue River, Connected Cannabis, DeLisioso, Khalifa Kush, Love’s Oven, Miami Mango, O.pen, Seed Junky, and Sunshine Cannabis, all available exclusively at Trulieve in Florida.

Across Florida, Trulieve offers home delivery, convenient online ordering, and in-store pickup. Veterans receive 20% off every order when they show their military ID, and all first-time guests are eligible for a 60% new customer discount at any Florida Trulieve location. For more information, or to learn how to become a registered patient, please visit Trulieve.com and connect on Instagram or Facebook.

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.

Facebook: @Trulieve
Instagram: @Trulieve_
X: @Trulieve

Investor Contact
Christine Hersey, Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Phil Buck, APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/trulieve-to-open-medical-cannabis-dispensary-in-orlando-florida-302279888.html

SOURCE Trulieve Cannabis Corp.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

mCig Inc. (MCIG ), Player’s Network, Inc. (PNTV ) Complete Phase 1 Construction for Production Facility

mCig, Inc. and Players Network, Inc. Announces Completion of Phase 1 Construction…

$SING Agrees to Acquire the Assets

Havana Holdings Inc. Agrees to Acquire the Assets of GreenStar From SinglePoint,…

Reliq Health Technologies Inc. (RQHTF) Announces Upcoming Shareholder Update Webinar

Reliq Health Technologies, Inc. Announces Upcoming Shareholder Update Webinar Reliq Health Technologies…

AbbVie Inc. (ABBV) and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets

AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage…